Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hormone Refractory Prostate Cancer Pipeline Review, H2 2016, provides an overview of the Hormone Refractory Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer no longer responds to hormone therapy and growth of the cancer continues, it is called hormone resistant or hormone refractory prostate cancer. This occurs if cancer cells do not need testosterone for growth. Symptoms include fatigue, blood in the urine, pain in the hips, back (spine), chest (ribs), or other areas from cancer spread to bones, loss of appetite, or weight loss. Predisposing factors include age, smoking and family history. Treatment includes chemotherapy and radiotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hormone Refractory Prostate Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hormone Refractory Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hormone Refractory Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 9, 57, 35, 1, 36 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 2, 7 and 4 molecules, respectively for Hormone Refractory Prostate Cancer.

Hormone Refractory Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hormone Refractory Prostate Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hormone Refractory Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hormone Refractory Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.